Head-to-head · WeighScore
Trimrose vs Zealthy
The verdict
Trimrose takes it — 55.2/100 to 46.7/100.
Trimrose grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trimrose (Trimrose Inc.) is a cash-pay telehealth platform for compounded GLP-1 weight loss, offered as a weekly injection or a daily oral option.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Trimrose | Zealthy |
|---|---|---|
| WeighScore | 55.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #446 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #446 · C
Strengths
- Free, no-cost, no-obligation online eligibility quiz before any commitment
- Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
- Fully online — assessment, provider review, and home delivery with ongoing support
Where it loses points
- Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
- Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
- The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
- Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.